ArticleFrontiers in immunology2025

Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience.

Yan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.